PCI-24781 (CRA-024781)
PCI-24781 (also known as CRA-024781) is a novel, broad spectrum inhibitor of HDACs that shows antitumor activity in vitro. PCI-24781 primarily targets HDAC1 (Ki = 7 nM) . It also exhibits modest potenty toward HDACs 2,3, 6, and 10 and greater than 40-fold selectivity against HDAC8.
Product Specifications
Background
PCI-24781 is a pan-HDAC inhibitor that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials for cancer, particularly B-cell lymphoma. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-?B mechanisms in Hodgkin lymphoma and non-Hodgkin lymphoma cell lines.
Solubility
Soluble in DMSO
Molecular Formula
C21H23N3O5
Shipping Conditions
Room Temperature (continental US) or Gel Packs
Storage Conditions
Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Calculated Molecular Weight
397.4 Da
CAS Number
783355-60-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
